Ishara Investments LP
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Ishara Investments LP reported 36 stock positions worth $99.0 million. Its top holding was Praxis Precision Medicines I (PRAX) at 7.3% of the portfolio, followed by Axsome Therapeutics (AXSM, 7.0%) and Xeris Biopharma (XERS, 6.0%). Compared with Q4 2025, it opened 17 new positions, sold out of 18, added to 10 and reduced 9. The biggest buy was a new position in Axsome Therapeutics (AXSM) and the biggest sale Praxis Precision Medicines I (PRAX, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- LOS ANGELES, CA
- CIK
- 0002111609
- Portfolio Value
- $99.0M (Q1 2026)
- SEC Filing
- 0002111609-26-000002 ↗ filed May 15, 2026
Holdings Value
Holdings 36 stocks · $99.0M
| PRAX Praxis Precision Medicines I | 7.34% | 22,550 | $7.3M | Reduce -43.6% |
| AXSM Axsome Therapeutics Inc. | 7.00% | 41,000 | $6.9M | New |
| XERS Xeris Biopharma Holdings Inc. | 6.00% | 1,025,000 | $5.9M | Add +28.1% |
| KALV Kalvista Pharmaceuticals Inc. | 5.63% | 276,750 | $5.6M | New |
| FOLD Amicus Therapeutics Inc. | 5.39% | 369,000 | $5.3M | Add +2.5% |
| BMRN Biomarin Pharmaceutical Inc. | 4.68% | 82,000 | $4.6M | Reduce -18.0% |
| VSTM Verastem Inc. | 4.39% | 820,000 | $4.3M | Add +203.7% |
| RARE Ultragenyx Pharmaceutical Inc. | 3.69% | 174,250 | $3.7M | Add +248.5% |
| ARWR Arrowhead Pharmaceuticals Inc. | 3.50% | 55,350 | $3.5M | New |
| PCVX Vaxcyte Inc. | 3.37% | 57,400 | $3.3M | Add +14.8% |
| VERA Vera Therapeutics Inc. | 3.33% | 82,000 | $3.3M | New |
| TVTX Travere Therapeutics Inc. | 3.32% | 110,700 | $3.3M | New |
| MLTX Moonlake Immunotherapeutics | 3.28% | 174,250 | $3.2M | New |
| ZNTL Zentalis Pharmaceuticals Inc. | 2.91% | 1,230,000 | $2.9M | Reduce -6.8% |
| SRRK Scholar Rock Holding Corp. | 2.85% | 57,400 | $2.8M | New |
| ACAD Acadia Pharmaceuticals Inc. | 2.77% | 123,000 | $2.7M | Reduce -23.1% |
| ARDX Ardelyx Inc. | 2.73% | 451,000 | $2.7M | New |
| MLYS Mineralys Therapeutics Inc. | 2.24% | 82,000 | $2.2M | New |
| GMAB Genmab A/S -SP ADR | 2.22% | 82,000 | $2.2M | Add +17.1% |
| DBVT DBV Technologies SA-Spon ADR | 2.16% | 102,500 | $2.1M | New |
| CPRX Catalyst Pharmaceuticals Inc. | 2.05% | 82,000 | $2.0M | New |
| SION Sionna Therapeutics Inc. | 1.99% | 49,200 | $2.0M | New |
| CTNM Contineum Therapeutics Inc. Class A | 1.87% | 142,000 | $1.9M | New |
| ALNY Alnylam Pharmaceuticals Inc. | 1.71% | 5,125 | $1.7M | New |
| LGND Ligand Pharmaceuticals | 1.65% | 8,200 | $1.6M | New |
| EWTX Edgewise Therapeutics Inc. | 1.57% | 49,200 | $1.5M | Reduce -15.2% |
| IMTX Immatics NV | 1.53% | 153,750 | $1.5M | Add +92.2% |
| LXRX Lexicon Pharmaceuticals Inc. | 1.42% | 902,000 | $1.4M | Add +2.5% |
| BEAM Beam Therapeutics Inc. | 1.38% | 57,400 | $1.4M | Add +14.8% |
| ORIC Oric Pharmaceuticals Inc. | 1.31% | 102,500 | $1.3M | Reduce -35.9% |
| NAMS Newamsterdam Pharma Co. NV | 1.19% | 36,900 | $1.2M | Add +23.0% |
| ANNX Annexon Inc. | 0.97% | 174,250 | $965K | Reduce -76.8% |
| IDYA Ideaya Biosciences Inc. | 0.83% | 24,600 | $820K | New |
| SLN Silence Therapeutics PLC-ADR | 0.75% | 140,500 | $740K | Reduce -41.5% |
| PTCT PTC Therapeutics Inc. | 0.71% | 10,250 | $698K | Reduce -71.5% |
| GOSS Gossamer Bio Inc. | 0.27% | 820,000 | $269K | New |
Options reported separately and not counted above: PRAX puts ($6.6M).
Portfolio Sells Q4 2025 → Q1 2026
| PRAX Praxis Precision Medicines I | Reduce -43.6% | 7.34% | −6.38 |
| NUVB Nuvation Bio Inc. | Sold out | 0.00% | −4.17 |
| ANNX Annexon Inc. | Reduce -76.8% | 0.97% | −3.41 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −3.20 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −3.12 |
| BCRX Biocryst Pharmaceuticals Inc. | Sold out | 0.00% | −2.72 |
| PTCT PTC Therapeutics Inc. | Reduce -71.5% | 0.71% | −2.48 |
| SNDX Syndax Pharmaceuticals Inc. | Sold out | 0.00% | −2.45 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −2.29 |
| BMRN Biomarin Pharmaceutical Inc. | Reduce -18.0% | 4.68% | −2.24 |
| ACAD Acadia Pharmaceuticals Inc. | Reduce -23.1% | 2.77% | −2.21 |
| APOG Apogee Enterprises Inc. | Sold out | 0.00% | −2.20 |
| INSM Insmed Inc. | Sold out | 0.00% | −2.03 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.46 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −1.34 |
| ASND Ascendis Pharma A/S | Sold out | 0.00% | −1.24 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.16 |
| DNTH Dianthus Therapeutics Inc. | Sold out | 0.00% | −1.15 |
| NKTR Nektar Therapeutics | Sold out | 0.00% | −0.98 |
| SLN Silence Therapeutics PLC-ADR | Reduce -41.5% | 0.75% | −0.95 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −0.95 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.89 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.87 |
| ARQT Arcutis Biotherapeutics Inc. | Sold out | 0.00% | −0.41 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -35.9% | 1.31% | −0.21 |
| EWTX Edgewise Therapeutics Inc. | Reduce -15.2% | 1.57% | −0.11 |
| ZNTL Zentalis Pharmaceuticals Inc. | Reduce -6.8% | 2.91% | +0.83 |
Portfolio Buys Q4 2025 → Q1 2026
| AXSM Axsome Therapeutics Inc. | New | 7.00% | +7.00 |
| KALV Kalvista Pharmaceuticals Inc. | New | 5.63% | +5.63 |
| ARWR Arrowhead Pharmaceuticals Inc. | New | 3.50% | +3.50 |
| VERA Vera Therapeutics Inc. | New | 3.33% | +3.33 |
| TVTX Travere Therapeutics Inc. | New | 3.32% | +3.32 |
| MLTX Moonlake Immunotherapeutics | New | 3.28% | +3.28 |
| SRRK Scholar Rock Holding Corp. | New | 2.85% | +2.85 |
| ARDX Ardelyx Inc. | New | 2.73% | +2.73 |
| RARE Ultragenyx Pharmaceutical Inc. | Add +248.5% | 3.69% | +2.35 |
| MLYS Mineralys Therapeutics Inc. | New | 2.24% | +2.24 |
| DBVT DBV Technologies SA-Spon ADR | New | 2.16% | +2.16 |
| CPRX Catalyst Pharmaceuticals Inc. | New | 2.05% | +2.05 |
| SION Sionna Therapeutics Inc. | New | 1.99% | +1.99 |
| VSTM Verastem Inc. | Add +203.7% | 4.39% | +1.96 |
| CTNM Contineum Therapeutics Inc. Class A | New | 1.87% | +1.87 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 1.71% | +1.71 |
| LGND Ligand Pharmaceuticals | New | 1.65% | +1.65 |
| IDYA Ideaya Biosciences Inc. | New | 0.83% | +0.83 |
| PCVX Vaxcyte Inc. | Add +14.8% | 3.37% | +0.68 |
| IMTX Immatics NV | Add +92.2% | 1.53% | +0.55 |
| GOSS Gossamer Bio Inc. | New | 0.27% | +0.27 |
| LXRX Lexicon Pharmaceuticals Inc. | Add +2.5% | 1.42% | +0.24 |
| NAMS Newamsterdam Pharma Co. NV | Add +23.0% | 1.19% | −0.03 |
| BEAM Beam Therapeutics Inc. | Add +14.8% | 1.38% | −0.23 |
| GMAB Genmab A/S -SP ADR | Add +17.1% | 2.22% | −0.29 |
| FOLD Amicus Therapeutics Inc. | Add +2.5% | 5.39% | −0.58 |
| XERS Xeris Biopharma Holdings Inc. | Add +28.1% | 6.00% | −1.30 |
Options Activity Q4 2025 → Q1 2026
| PRAX Praxis Precision Medicines I | put | New | 20,500 | $6.6M |
| CORT Corcept Therapeutics Inc. | call | Sold out | 44,000 | $1.5Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.